Slowing down mRNA translation in either the cytoplasm or the mitochondria are conserved longevity mechanisms. Here, we found a non-interventional natural correlation of mitochondrial and cytoplasmic ribosomal proteins (RPs) in mouse population genetics, suggesting a translational balance between these two compartments. Inhibiting mitochondrial translation in C. elegans through mrps-5 RNAi repressed overall cytoplasmic translation. Transcriptomics integrated with proteomics revealed that this inhibition specifically reduced the translational efficiency (TE) of mRNAs required in growth pathways while increasing the TE of stress response mRNAs. The coordinated repression of cytoplasmic translation is dependent on atf-5/Atf4 and is conserved in mammalian cells upon inhibiting mitochondrial translation pharmacologically with the antibiotic doxycycline. Lastly, extending this in vivo, doxycycline repressed cytoplasmic translation and RP expression in the livers of germ-free mice. These data demonstrate that inhibiting mitochondrial translation initiates an atf-5/Atf4-dependent cascade leading to coordinated repression of cytoplasmic translation, which could be targeted to promote longevity. Keywords longevity / ribosomes / mitochondrial translation / cytoplasmic translation / translational balance Highlights • Mitochondrial and cytoplasmic RP levels balance in a natural stoichiometric ratio • Blocking mitochondrial ribosomes in worms and mice reduces cytoplasmic translation • This translational balance is ATF4/atf-5 dependent and conserved in human cells • Translational efficiency of RP transcripts changes in response to ratio requirement

The deregulation of metabolism is a hallmark of aging. As such, changes in the expression of metabolic genes and the profiles of amino acid levels are features associated with aging animals. We previously reported that the levels of most amino acids decline with age in Caenorhabditis elegans (C. elegans). Glycine, in contrast, substantially accumulates in aging C. elegans. In this study we show that this is coupled to a decrease in gene expression of enzymes important for glycine catabolism. We further show that supplementation of glycine significantly prolongs C. elegans lifespan, and early adulthood is important for its salutary effects. Moreover, supplementation of glycine ameliorates specific transcriptional changes that are associated with aging. Glycine feeds into the methionine cycle. We find that mutations in components of this cycle, methionine synthase (metr-1) and S-adenosylmethionine synthetase (sams-1), completely abrogate glycine-induced lifespan extension. Strikingly, the beneficial effects of glycine supplementation are conserved when we supplement with serine, which also feeds into the methionine cycle. RNA-sequencing reveals a similar transcriptional landscape in serine- and glycine-supplemented worms both demarked by widespread gene repression. Taken together, these data uncover a novel role of glycine in the deceleration of aging through its function in the methionine cycle.

Reversing or slowing the aging process brings great promise to treat or prevent age‐related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for intervention. One component of epigenetic regulation involves histone deacetylases (HDAC), which include the “classical” histone deacetylases (of class I, II, and IV) and sirtuin deacetylases (of class III). While targeting sirtuins for healthy aging has been extensively reviewed elsewhere, this review focuses on pharmacologically inhibiting the classical HDACs to promote health and longevity. We describe the theories of how classical HDAC inhibitors may operate to increase lifespan, supported by studies in model organisms. Furthermore, we explore potential mechanisms of how HDAC inhibitors may have such a strong grasp on health and longevity, summarizing their links to other hallmarks of aging. Finally, we show the wide range of age‐related preclinical disease models, ranging from neurodegeneration to heart disease, diabetes to sarcopenia, which show improvement upon HDAC inhibition.